pharma · Non-transfusion-dependent Thalassemia · Advanced Solid Tumors · SLN
Silence Therapeutics
Silence Therapeutics plc
Silence Therapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- London, GB
- Founded
- 1999
- Employees
- 91
- Programs
- 8
- Drugs
- 6
- Patents
- 3
Silence Therapeutics projects
8 ClinicalTrials.gov programs sponsored by Silence Therapeutics.
Silence Therapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Atu027 & gemcitabine in lead in safety period
Silence Therapeutics plc
Carcinoma, Pancreatic Ductal
1 trial -
SLN124
Silence Therapeutics plc
Polycythemia Vera
1 trial -
SLN360
Silence Therapeutics plc
Cardiovascular Diseases
1 trial -
Atu027
Silence Therapeutics plc
Advanced Solid Tumors
1 trial -
SLN124
Silence Therapeutics plc
Non-transfusion-dependent Thalassemia
1 trial -
SLN124
Silence Therapeutics plc
Healthy Volunteers
1 trial -
SLN124-001
Silence Therapeutics plc
Non-transfusion-dependent Thalassemia
1 trial -
SLN360
Silence Therapeutics plc
Hyperlipidemias
1 trial
Frequently asked questions
How many clinical projects does Silence Therapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.